The molecular structure of the first orally active carbapenem antibacterial agent, tebipenem pivoxil (systematic name: (2,2-dimethylpropanoyloxy)methyl
The molecular structure of the first orally active carbapenem antibacterial agent, tebipenem pivoxil (systematic name: (2,2-dimethylpropanoyloxy)methyl (4R,5S,6S)-3-{[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate), C 22 H 31 N 3 O 6 S 2 , has been determined and the configurations of the four chiral centers validated. The title compound crystallizes in the triclinic space group P1 with one molecule in the unit cell. Three out of the four rings adopt planar conformations while the thiazolinyl ring adopts an enveloped conformation. In the crystal, O-HÁ Á ÁN hydrogen bonds link the molecules into chains along [110] .
Chemical context
Carbapenem antibiotics, like all -lactam antibacterials that bind to and inhibit the peptidoglycan cross-linking transpeptidases, have attracted increasing attention recently because of their broader spectrum activities and stronger bactericidal actions compared to cephalosporins and penicillins. Since the first carbapenem structure thienamycin, a natural product derived from Streptomyces cattleya, was isolated in 1976 (Johnston et al., 1978) , a handful of subsequent parenteral carbapenem agents, such as imipenem, panipenem, meropenem, biapenem, have been developed based on this parent compound and used clinically for the treatment of severe bacterial infections.
Tebipenem pivoxil (see scheme), as a novel oral carbapenem agent, was approved by the Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on Apr 22, 2009. It was developed and marketed as Orapenem1 by Meiji Seika in Japan (as of 05/16/2016, the only approved country/area for its usage was Japan for treating children, as these oral antibiotics are often better tolerated than infusions) (Kijima et al., 2009) . It is a prodrug that is quickly hydrolysed to the active antimicrobial agent LJC11,036 (5, reaction scheme) because the absorption rate of the pivaloyloxymethyl ester is higher than that of other prodrug-type -lactam antibiotics (Kato et al., 2010) . The active metabolite 5 shows potent and well- ISSN 2056-9890 balanced antibacterial activity and also shows higher stability to human renal dehydropeptidase-I than meropenem (Isoda et al., 2006a; Kobayashi et al., 2005) . Research has also revealed that the tebipenbem acyl--lactamase covalent complex remains very stable for longer than 90 min, partly explaining its resistance towards hydrolysis (Papp-Wallace et al., 2011) .
Tebipenem pivoxil has a complex structure with four chiral centers and a 1-(1,3-thiazolin-2-yl)azetidin-3-ylthio side chain at the C-2 position. We hope the structural elucidation will facilitate future mechanistic studies of this molecule and of its interactions with enzymes that are responsible for bacterial resistance.
Structural commentary
Tebipenem pivoxil (Fig. 1 ) crystallizes in the triclinic space group P1 with one molecule in the unit cell. The present crystal structure dertermination allowed the configurations of the four chiral centers to be validated as: C2S, C3S, C4R, C7R. Rings I (N1/C1-C3), II (N1/C3-C6) and III (N2/C11-C13) adopt planar conformations (with r.m.s. deviations of 0.0251, 0.0838, and 0.0967 Å , respectively) while ring IV (N3/S2/C14-C16) adopts an envelope conformation with atom C16 as the flap. The dihedral angles between rings I and II, II and III, and III and IV are 46.7 (2), 85.7 (2), and 11.9 (4) , respectively. Atoms C9 (methyl) and C7 are located above and below the planes of rings I and II because of steric hindrance.
Supramolecular features
In the crystal, O-HÁ Á ÁN hydrogen bonds (Table 1) link the molecules into chains along [110] . C-HÁ Á ÁO hydrogen bonds are also observed. The packing viewed along the a axis is shown in Fig. 2. 
Database survey
The tebipenem pivoxil we obtained was well characterized spectroscopically and carefully compared with reference values (Isoda et al., 2006a) . To the best of our knowledge, including a search of the Cambridge Structural Database (CSD Version 5.39; Groom et al., 2016) , no single crystal structure determination has previously been reported for this drug.
Synthesis and crystallization
As shown in the reaction scheme (also see Supporting Information), 3-mercapto-1-(1,3-thiazolin-2-yl)-azetidine hydrochloride (3) was first synthesized according to a method previously reported (Isoda et al., 2006b ) with minor optimizations. The side chain 3 was then coupled with the commercially available carbapenem core (2), followed by hydrogenation/deprotection and SN 2 esterification to afford the desired tebipenem pivoxil 1 (Isoda et al., 2006a,b The crystal packing viewed along the crystallographic a axis showing the O-HÁ Á ÁN hydrogen bonds (Table 1) as dashed lines.
Figure 1
The molecular structure of the title compound, showing the atom labelling and 30% probability displacement ellipsoids. Table 1 Hydrogen-bond geometry (Å , ). Symmetry codes: (i) x À 1; y þ 1; z; (ii) x; y À 1; z.
of using column chromatography, we successfully obtained pure tebipenem pivoxil on a relatively large scale through recrystallization from ethyl acetate, yielding colourless blockshaped crystals. The HPLC spectrum of the final product showed a single peak with less than 0 (Isoda et al., 2006a) .
Refinement
Crystal data, data collection and structure refinement details are summarized in Table 2 . In the refinement, all H atoms were positioned geometrically and refined as riding: C-H = 0.96-0.98 Å with U iso (H) = 1.2U eq (C) or 1.5U eq (C-methyl). Computer programs: APEX2 and SAINT (Bruker, 2014) , SHELXS2018/3 and SHELXTL (Sheldrick, 2008) and SHELXL2018/3 (Sheldrick, 2015) .
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Special details
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. 1.551 (6) C20-H20B 0.9600 C3-H3B 0.9800 C20-H20C 0.9600 C4-C9
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (
1.527 (7) C21-H21A 0.9600 C4-C5
1.528 (6) C21-H21B 0.9600 C4-H4A 0.9800 C21-H21C 0.9600 C5-C6
1.342 (6) C22-H22A 0.9600
